Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

← catalyst calendar

NCT07135986

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Prevention

Enrollment

1,602actual

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-09-26

actual

When the study began enrolling

Primary completion

2026-05-01

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-09-23

estimated

The whole study's end, after follow-up

First posted

2025-08-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Meningococcal Infection
Healthy Volunteers

Interventions

Biological: MenACYW conjugate vaccine — also filed as MenQuadfi
Biological: MenACYW135 polysaccharide vaccine
Biological: MenAC conjugate vaccine

Primary outcomes

what the primary-completion date above is the date OF

Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W